SCHEMBL3547754

SCHEMBL3547754

CC(=O)c1ccccc1-c1nc(C(=O)NCCC2CCCCC2)cs1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 2/20 0.52
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PANK3 Q9H999 1/20 0.44
TYR P14679 1/20 0.43
CHRM1 P11229 2/20 0.43
PIN1 Q13526 1/20 0.41
HIF1A Q16665 1/20 0.40
USP30 Q70CQ3 1/20 0.40
HPGDS O60760 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
TBXA2R P21731 2/20 0.39
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3535409 0.85 PANK3 (0.53) ACKR3NPC1RAB9AL3MBTL1PANK3
SCHEMBL3543022 0.84 TYR (0.61) NPC1RAB9ATYRPIN1HPGD
SCHEMBL3545631 0.84 ACKR3 (0.69) ACKR3NPC1RAB9AL3MBTL1PIN1
SCHEMBL2027225 0.84 TYR (0.61) NPC1RAB9ATYRPIN1HPGD
SCHEMBL3537090 0.81 PANK3 (0.64) ACKR3NPC1RAB9AL3MBTL1PANK3
SCHEMBL3536962 0.74 CHRM1 (0.53) ACKR3NPC1RAB9AL3MBTL1PANK3
SCHEMBL3547753 0.74 SLC6A9 (0.44) NPC1RAB9AL3MBTL1ADORA2A
SCHEMBL3538123 0.73 USP30 (0.51) ACKR3NPC1TYRCHRM1PIN1
SCHEMBL2026844 0.73 TYR (0.44) NPC1RAB9ATYRPIN1HIF1A
SCHEMBL2026842 0.73 TYR (0.44) NPC1RAB9ATYRPIN1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645773-B2 Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-01-12 US disclosed
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GILLESPIE PAUL 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167622-A1 [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome GOT2, PC, CYP11B2 ACKR3 3834/4885NPC1 891/4885RAB9A 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.